John Valliant - 01 Feb 2022 Form 4 Insider Report for Fusion Pharmaceuticals Inc. (FUSN)

Role
Chief Executive Officer, Director
Signature
/s/Maria Stahl as Attorney-in-Fact for John Valliant
Issuer symbol
FUSN
Transactions as of
01 Feb 2022
Transactions value $
$0
Form type
4
Filing time
03 Feb 2022, 18:40:31 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FUSN Stock Option (Right to Buy) Award $0 +406,600 $0 406,600 01 Feb 2022 Common Stock 406,600 $7.7 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in 48 equal monthly installments beginning on March 1, 2022.